Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review.
Myriam MirzaLutz GoerkeAnna AndersonTim WilsdonPublished in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2024)
Current literature supports NGS's cost-effectiveness as an oncology biomarker testing strategy under specific conditions. These findings underscore the need to develop policies to support holistic assessment of NGS to ensure appropriate reimbursement and access.